Novasep

KBI Biopharma Appoints Jean-Baptiste Agnus as Chief Business Officer

Retrieved on: 
Monday, April 15, 2024
Other Manufacturing, Research, Manufacturing, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Chemical engineering, Growth, Novasep, CDMO, Patient, Multimedia, KBI, API, Spacecraft, CGMP

KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and global cGMP contract development and manufacturing organization (CDMO), today announced the appointment of Jean-Baptiste (JB) Agnus as Chief Business Officer, solidifying KBI’s Executive Team.

Key Points: 
  • KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and global cGMP contract development and manufacturing organization (CDMO), today announced the appointment of Jean-Baptiste (JB) Agnus as Chief Business Officer, solidifying KBI’s Executive Team.
  • “Our dedication to growth and commitment to our partners, their patients, and our people guide every decision at KBI Biopharma,” remarked J.D.
  • His servant leadership philosophy will further fortify our team, propelling KBI to new heights.”
    “KBI Biopharma is an innovator in the testing, development, manufacturing, and commercialization of life-changing therapies,” said JB Agnus, Chief Business Officer of KBI Biopharma.
  • I am excited to join the passionate team at KBI, who are committed to ensuring transformative treatments reach those in need by nurturing meaningful customer relationships.”
    Before joining KBI, JB held leadership roles in business development at AGC Biologics, Ajinomoto Bio-Pharma Services, Novasep, and Isochem.

Quotient Sciences Strengthens Its Top Team with Three New Appointments

Retrieved on: 
Monday, March 18, 2024
Quotient, Patient, Ipsen, Business development, Senior, Drug development, Ciarán, Translation, Novasep, Consultant, Marketing, Management

NOTTINGHAM, England, March 18, 2024 /PRNewswire/ -- Drug development and manufacturing accelerator Quotient Sciences has announced major changes to its commercial and scientific executive leadership team, strengthening its position as a global leader in the sector.

Key Points: 
  • Andrew will lead the team of Drug Development Consultants and Scientific Research Fellows to grow Quotient Sciences' global scientific expertise and recognition.
  • During his eight years with Quotient Sciences, Andrew has held various scientific leadership positions, most recently as Senior Vice President, Pharmaceutical Development.
  • He was Head of Business Development in Europe for Cyprotex (an Evotec company) before joining Quotient Sciences.
  • Eric Bironneau has joined the company as Chief Business Officer, with responsibility for Quotient Sciences' commercial organization across drug substance, drug product, and Translational Pharmaceutics® commercial lines, as well as for Quotient Sciences' strategic partnerships.

Quotient Sciences Strengthens Its Top Team with Three New Appointments

Retrieved on: 
Monday, March 18, 2024
Quotient, Patient, Ipsen, Business development, Senior, Drug development, Ciarán, Translation, Novasep, Consultant, Marketing, Management

NOTTINGHAM, England, March 18, 2024 /PRNewswire/ -- Drug development and manufacturing accelerator Quotient Sciences has announced major changes to its commercial and scientific executive leadership team, strengthening its position as a global leader in the sector.

Key Points: 
  • Andrew will lead the team of Drug Development Consultants and Scientific Research Fellows to grow Quotient Sciences' global scientific expertise and recognition.
  • During his eight years with Quotient Sciences, Andrew has held various scientific leadership positions, most recently as Senior Vice President, Pharmaceutical Development.
  • He was Head of Business Development in Europe for Cyprotex (an Evotec company) before joining Quotient Sciences.
  • Eric Bironneau has joined the company as Chief Business Officer, with responsibility for Quotient Sciences' commercial organization across drug substance, drug product, and Translational Pharmaceutics® commercial lines, as well as for Quotient Sciences' strategic partnerships.

EQS-News: Sartorius expects profitable growth in 2024; double-digit annual sales revenue growth projected through to 2028

Retrieved on: 
Tuesday, January 30, 2024
CO2, Patient, Deleveraging, Forecasting, Research, Sartorius, Face, Electricity, Novasep, Public expenditure, Acquisition, Sartorius AG, Acceleration, Transfection, Weakness, Vaccine, News, Growth

Sartorius expects profitable growth in 2024; double-digit annual sales revenue growth projected through to 2028 (news with additional features)

Key Points: 
  • Sartorius expects profitable growth in 2024; double-digit annual sales revenue growth projected through to 2028 (news with additional features)
    The issuer is solely responsible for the content of this announcement.
  • Sales revenue in the Americas region was down 14.9 percent and accounted for around 38 percent of the Group total.
  • In the Asia | Pacific region, in particular, the pronounced weakness of the market in China had a significant impact, with sales revenue down 22.1 percent.
  • Sartorius intends to continue its profitable growth path in the long term and expects to grow faster than the market.

Highly experienced CDMO expert Michel Spagnol appointed Chairman of Astraveus

Retrieved on: 
Tuesday, November 28, 2023
Merck Group, CDMO, Patient, SAB, Stanford University, Knowledge, CGT, Management, Novasep

PARIS, Nov. 28, 2023 /PRNewswire/ -- Astraveus SAS ("Astraveus" or the "Company"), the creator of modular, microfluidic cell foundries that transform cell and gene therapy (CGT) manufacturing, today announces the appointment of Michel Spagnol as its new Chairman of the Board.

Key Points: 
  • PARIS, Nov. 28, 2023 /PRNewswire/ -- Astraveus SAS ("Astraveus" or the "Company"), the creator of modular, microfluidic cell foundries that transform cell and gene therapy (CGT) manufacturing, today announces the appointment of Michel Spagnol as its new Chairman of the Board.
  • Michel, a Stanford PhD graduate, brings a wealth of experience and expertise to Astraveus.
  • Michel currently serves as Deputy Chairman at Axplora group, and as a Board member and Chairman of the SAB at MVG Group.
  • The Company recently completed a €16.5 million seed financing to significantly advance the development of its technology and expand the team.

Highly experienced CDMO expert Michel Spagnol appointed Chairman of Astraveus

Retrieved on: 
Tuesday, November 28, 2023
Merck Group, CDMO, Patient, SAB, Stanford University, Knowledge, CGT, Management, Novasep

PARIS, Nov. 28, 2023 /PRNewswire/ -- Astraveus SAS ("Astraveus" or the "Company"), the creator of modular, microfluidic cell foundries that transform cell and gene therapy (CGT) manufacturing, today announces the appointment of Michel Spagnol as its new Chairman of the Board.

Key Points: 
  • PARIS, Nov. 28, 2023 /PRNewswire/ -- Astraveus SAS ("Astraveus" or the "Company"), the creator of modular, microfluidic cell foundries that transform cell and gene therapy (CGT) manufacturing, today announces the appointment of Michel Spagnol as its new Chairman of the Board.
  • Michel, a Stanford PhD graduate, brings a wealth of experience and expertise to Astraveus.
  • Michel currently serves as Deputy Chairman at Axplora group, and as a Board member and Chairman of the SAB at MVG Group.
  • The Company recently completed a €16.5 million seed financing to significantly advance the development of its technology and expand the team.

EQS-News: SARTORIUS AG: Sartorius nine-month figures: Normalization of demand continues after end of pandemic

Retrieved on: 
Thursday, October 26, 2023
Quotient, Sartorius AG, Federal Executive Boards, Vaccine, Public expenditure, EBITDA, Acquisition, CEST, Research, Sartorius, Novasep, CFO, ID Labs production discography, Forecasting, Security (finance), Pharmaceutical industry, Fine chemical, Cryptocurrency, Arms industry, Management

For the full year, Sartorius expects a decline in sales revenue by approximately 17 percent, with an underlying EBITDA margin of slightly above 28 percent.

Key Points: 
  • For the full year, Sartorius expects a decline in sales revenue by approximately 17 percent, with an underlying EBITDA margin of slightly above 28 percent.
  • “2023 will be a year of normalization for Sartorius as well as for the market as a whole.
  • The reduction of inventories by our customers after the end of the pandemic is taking longer than expected and is thus delaying the recovery.
  • Sartorius assumes no liability for updating such statements in light of new information or future events.

Quotient Sciences Appoints Thierry Van Nieuwenhove as New CEO

Retrieved on: 
Monday, October 16, 2023
Quotient, Investment, The Home Depot, Retirement, Lytx, Drug development, Business, Geraardsbergen, Senior advisor, UPS, Wells Fargo, Growth, API, Novasep, CDMO, Synthesis, Patient, Pharmaceutical industry, Management, Cambrex Corporation, Permira

Van Nieuwenhove succeeds Mark Egerton, who retires after 18 years in the role

Key Points: 
  • Van Nieuwenhove succeeds Mark Egerton, who retires after 18 years in the role
    NOTTINGHAM, England, Oct. 16, 2023 /PRNewswire/ -- Quotient Sciences ("Quotient" or the "Company"), a leading global pharmaceutical drug development and manufacturing accelerator, is pleased to announce the appointment of Thierry Van Nieuwenhove as its new Chief Executive Officer (CEO), effective 16thOctober 2023.
  • Thierry succeeds Mark Egerton who, after 18 years of successfully leading Quotient as CEO, is retiring from executive life.
  • Thierry Van Nieuwenhove joins Quotient with an extensive track record in the pharma/CDMO services industry spanning over 23 years, and with experience in both small molecules and biologics.
  • Thierry Van Nieuwenhove said: "I am honoured to join Quotient as its new CEO and lead a team dedicated to improving the lives of patients worldwide.

Quotient Sciences Appoints Thierry Van Nieuwenhove as New CEO

Retrieved on: 
Monday, October 16, 2023
Quotient, Investment, The Home Depot, Retirement, Lytx, Drug development, Business, Geraardsbergen, Senior advisor, UPS, Wells Fargo, Growth, API, Novasep, CDMO, Synthesis, Patient, Pharmaceutical industry, Management, Cambrex Corporation, Permira

Van Nieuwenhove succeeds Mark Egerton, who retires after 18 years in the role

Key Points: 
  • Van Nieuwenhove succeeds Mark Egerton, who retires after 18 years in the role
    NOTTINGHAM, England, Oct. 16, 2023 /PRNewswire/ -- Quotient Sciences ("Quotient" or the "Company"), a leading global pharmaceutical drug development and manufacturing accelerator, is pleased to announce the appointment of Thierry Van Nieuwenhove as its new Chief Executive Officer (CEO), effective 16thOctober 2023.
  • Thierry succeeds Mark Egerton who, after 18 years of successfully leading Quotient as CEO, is retiring from executive life.
  • Thierry Van Nieuwenhove joins Quotient with an extensive track record in the pharma/CDMO services industry spanning over 23 years, and with experience in both small molecules and biologics.
  • Thierry Van Nieuwenhove said: "I am honoured to join Quotient as its new CEO and lead a team dedicated to improving the lives of patients worldwide.

Flash Therapeutics Appoints Jérôme Bédier as President to Accelerate its Biopharmaceutical CDMO Business Development

Retrieved on: 
Thursday, July 6, 2023
Research, Medical Supplies, Genetics, Health Technology, Biometrics, Other Health, Biotechnology, Pharmaceutical, Health, Science, Biopharmaceutical, GMP, DNA, Benitec Biopharma, RNA, Novasep, CDMO, Patient, Therapy, Vaccine

Jérôme Bédier, 49 years old, is an expert in the biomanufacturing and CDMO sector, to which he has devoted a large part of his career.

Key Points: 
  • Jérôme Bédier, 49 years old, is an expert in the biomanufacturing and CDMO sector, to which he has devoted a large part of his career.
  • With 25 years of experience, most particularly with the Novasep group, Jérôme Bédier held positions in business development and operations management before taking over strategic management of Novasep's Biopharmaceutical business and its three European sites.
  • "We are delighted to welcome Jérôme Bédier, an expert in biomanufacturing and service to the biopharmaceutical industry, to the executive management of Flash Therapeutics.
  • Jérôme Bédier added: "I am very pleased to join Flash Therapeutics in Toulouse.